New prognostic marker identified for gastric cancer recurrence risk

FHS
July 30, 2024
2:28 pm

Surgical removal of the tumor is considered the basis for curing gastric cancer. However, 40 per cent of patients who have undergone surgery suffer a relapse within two years.

RadioGel Precision Radionuclide Therapy Receives FDA Breakthrough Device Designation – Biotech Investments

EQS-News: Vivos Inc. / Key word(s): Miscellaneous RadioGel Precision Radionuclide Therapy Receives FDA Breakthrough Device Designation 20.12.2023 / 16:30 CET/CEST The issuer is solely responsible

December 21, 2023

Research shows how the immune system keeps Herpes simplex virus at bay

Herpes simplex virus (HSV) is extremely common, affecting nearly two-thirds of the world’s population, according to the World Health Organization.

December 15, 2023

B-Cell Depletion Helps Maintain Kidney Function in Lupus Nephritis

SAN DIEGO — Treatment with the B-cell depleting agent obinutuzumab (Gazyva) helped patients with lupus nephritis avoid the most serious adverse outcomes, according to a

November 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.